Investors
A Fast Growing Contender in Global Generics
Newsroom
In Focus
Investors
12 January 2026
Lotus Reports December 2025 Revenue of NT$2,442 Million, Driven by Consolidation of Strategic Alvogen US Acquisition
Investors
10 December 2025
Lotus Reports November 2025 Revenue of NT$1,059 Million
Investors
12 November 2025
Lotus Pharmaceutical Reports Results for the Third Quarter and First Nine Months of 2025
Stock Information
Lotus is listed on Taiwan Stock Exchange
Code: 1795
TWSE, Taipei 101
Links